Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 60

1.

Targeting cancer stem cells and signaling pathways by phytochemicals: Novel approach for breast cancer therapy.

Dandawate PR, Subramaniam D, Jensen RA, Anant S.

Semin Cancer Biol. 2016 Oct;40-41:192-208. doi: 10.1016/j.semcancer.2016.09.001. Epub 2016 Sep 5. Review.

PMID:
27609747
2.

Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.

Sharma P, López-Tarruella S, García-Saenz JA, Ward C, Connor CS, Gómez HL, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell AC, Del Monte-Millán M, Gonzalez-Rivera M, Massarrah T, Pelaez-Lorenzo B, Palomero MI, González Del Val R, Cortes J, Fuentes Rivera H, Bretel Morales D, Márquez-Rodas I, Perou CM, Wagner JL, Mammen JM, McGinness MK, Klemp JR, Amin AL, Fabian CJ, Heldstab J, Godwin AK, Jensen RA, Kimler BF, Khan QJ, Martin M.

Clin Cancer Res. 2017 Feb 1;23(3):649-657. doi: 10.1158/1078-0432.CCR-16-0162. Epub 2016 Jun 14.

3.

BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function.

Kumaraswamy E, Wendt KL, Augustine LA, Stecklein SR, Sibala EC, Li D, Gunewardena S, Jensen RA.

Oncogene. 2015 Aug 13;34(33):4333-46. doi: 10.1038/onc.2014.363. Epub 2014 Nov 24.

4.

The prognostic value of <i>BRCA1</i> promoter methylation in early stage triple negative breast cancer.

Sharma P, Stecklein SR, Kimler BF, Sethi G, Petroff BK, Phillips TA, Tawfik OW, Godwin AK, Jensen RA.

J Cancer Ther Res. 2014 Mar 19;3(2):1-11. doi: 10.7243/2049-7962-3-2.

5.

Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.

Sharma P, Klemp JR, Kimler BF, Mahnken JD, Geier LJ, Khan QJ, Elia M, Connor CS, McGinness MK, Mammen JM, Wagner JL, Ward C, Ranallo L, Knight CJ, Stecklein SR, Jensen RA, Fabian CJ, Godwin AK.

Breast Cancer Res Treat. 2014 Jun;145(3):707-14. doi: 10.1007/s10549-014-2980-0. Epub 2014 May 7.

6.

PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis.

Paul A, Gunewardena S, Stecklein SR, Saha B, Parelkar N, Danley M, Rajendran G, Home P, Ray S, Jokar I, Vielhauer GA, Jensen RA, Tawfik O, Paul S.

Cell Death Differ. 2014 Sep;21(9):1469-81. doi: 10.1038/cdd.2014.62. Epub 2014 May 2.

7.

The role of BRCA1 and BRCA2 in prostate cancer.

Li D, Kumaraswamy E, Harlan-Williams LM, Jensen RA.

Front Biosci (Landmark Ed). 2013 Jun 1;18:1445-59.

PMID:
23747895
8.

BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation.

Stecklein SR, Kumaraswamy E, Behbod F, Wang W, Chaguturu V, Harlan-Williams LM, Jensen RA.

Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13650-5. doi: 10.1073/pnas.1203326109. Epub 2012 Aug 6.

9.

Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology.

Stecklein SR, Jensen RA.

Transl Res. 2012 Sep;160(3):178-97. doi: 10.1016/j.trsl.2012.01.022. Epub 2012 Feb 9. Review.

PMID:
22683426
10.

Genetic and epigenetic signatures of breast cancer subtypes.

Stecklein SR, Jensen RA, Pal A.

Front Biosci (Elite Ed). 2012 Jan 1;4:934-49. Review.

PMID:
22201926
11.

A human breast cell model of preinvasive to invasive transition.

Rizki A, Weaver VM, Lee SY, Rozenberg GI, Chin K, Myers CA, Bascom JL, Mott JD, Semeiks JR, Grate LR, Mian IS, Borowsky AD, Jensen RA, Idowu MO, Chen F, Chen DJ, Petersen OW, Gray JW, Bissell MJ.

Cancer Res. 2008 Mar 1;68(5):1378-87. doi: 10.1158/0008-5472.CAN-07-2225.

12.

Excellent survival, cancer type, and Nottingham grade after atypical lobular hyperplasia on initial breast biopsy.

McLaren BK, Schuyler PA, Sanders ME, Jensen RA, Simpson JF, Dupont WD, Page DL.

Cancer. 2006 Sep 15;107(6):1227-33.

13.

Gene therapy for breast and ovarian cancer with BRCA1.

Tait DL, Jensen RA, Holt JT, Johnson DH, Gralow J, King MC.

Breast Dis. 1998 Apr;10(1-2):89-98.

PMID:
15687552
14.

Lobulocentricity of breast hypersecretory hyperplasia with cytologic atypia: infrequent association with carcinoma in situ.

Kasami M, Jensen RA, Simpson JF, Page DL.

Am J Clin Pathol. 2004 Nov;122(5):714-20.

PMID:
15491967
15.

Proteomics in diagnostic pathology: profiling and imaging proteins directly in tissue sections.

Chaurand P, Sanders ME, Jensen RA, Caprioli RM.

Am J Pathol. 2004 Oct;165(4):1057-68. Review.

16.

Genetically engineered mouse models of mammary intraepithelial neoplasia.

Cardiff RD, Moghanaki D, Jensen RA.

J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):421-37. Review.

PMID:
14973386
17.

Historical and epidemiologic background of human premalignant breast disease.

Page DL, Jensen RA, Simpson JF, Dupont WD.

J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):341-9. Review.

PMID:
14973380
18.

Metaplastic spindle cell breast tumors arising within papillomas, complex sclerosing lesions, and nipple adenomas.

Gobbi H, Simpson JF, Jensen RA, Olson SJ, Page DL.

Mod Pathol. 2003 Sep;16(9):893-901.

19.
20.

Ductal carcinoma in situ of the breast: impact of pathology on therapeutic decisions.

Jensen RA, Page DL.

Am J Surg Pathol. 2003 Jun;27(6):828-31.

PMID:
12766588

Supplemental Content

Loading ...
Support Center